Thursday, April 12, 2012
A University of California, San Francisco team has created a new class of reversible, covalent
small molecule kinase inhibitors that could be more selective and safer than
previous kinase inhibitors.1 Principia Biopharma Inc. has exclusively licensed the technology and plans to
develop new compounds to treat cancer and autoimmune diseases.
Osherovich, L. SciBX 5(15);
Published online April 12, 2012
1. Serafimova, I.M. et al. Nat. Chem.
Biol.; published online April 1,
Contact: Jack Taunton, University of California, San
2. Flanagan, M. BioCentury 20(5), A7; Jan. 30,
Celgene Corp. (NASDAQ:CELG), Summit, N.J.
Howard Hughes Medical Institute, Chevy Chase, Md.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Mission Bay Capital, San Francisco, Calif.
Morgenthaler Ventures, Menlo Park, Calif.
New Leaf Venture Partners, New York, N.Y.
OrbiMed Advisors LLC, New York, N.Y.
Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif.
Principia Biopharma Inc., South San Francisco, Calif.
University of California, San Francisco, Calif.
University of Rochester, Rochester, N.Y.